Metformin use and survival of patients with pancreatic cancer: A cautionary lesson

Journal of Clinical Oncology

Volumn 34, Issue 16, 2016, Pages 1898-1904

  Chaiteerakij, Roongruedee ^a,c   Petersen, Gloria M ^b   Bamlet, William R ^b   Chaffee, Kari G ^b   Zhen, David B ^b,d   Burch, Patrick A ^b   Leof, Emma R ^b   Roberts, Lewis R ^a   Oberg, Ann L ^b  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PATIENT SELECTION; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADENOCARCINOMA; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; METFORMIN; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84973162069     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.3511     Document Type: Article

References (20)

1. American Cancer Society: Cancer Facts & Figures 2016. Atlanta, GA, American Cancer Society, 2016
2. Smith BD, Smith GL, Hurria A, et al: Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 27:2758-2765, 2009
3. Gandini S, Puntoni M, Heckman-Stoddard BM, et al: Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 7:867-885, 2014
4. Zhang ZJ, Li S: The prognostic value of metformin for cancer patients with concurrent diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 16:707-710, 2014
5. Sadeghi N, Abbruzzese JL, Yeung SC, et al: Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18:2905-2912, 2012
6. Reference deleted
7. Pollak M: Overcoming drug development bottlenecks with repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. Nat Med 20:591-593, 2014
8. National Institutes of Health: ClinicalTrials.gov. https://clinicaltrials.gov/
9. Suissa S, Azoulay L: Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 35:2665-2673, 2012
10. Zhou Z, Rahme E, Abrahamowicz M, et al: Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: A comparison of methods. Am J Epidemiol 162:1016-1023, 2005
11. Suissa S: Immortal time bias in pharmacoepidemiology. Am J Epidemiol 167:492-499, 2008
12. Suissa S: Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16:241-249, 2007
13. Petersen GM, de Andrade M, Goggins M, et al: Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 15:704-710, 2006
14. American Diabetes Association: Standards of medical care in diabetes-2011. Diabetes Care 34:S11-S61, 2011 (suppl 1)
15. Fisher LD, Lin DY: Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20:145-157, 1999
16. Morales DR, Morris AD: Metformin in cancer treatment and prevention. Annu Rev Med 66:17-29, 2015
17. van Walraven C, Davis D, Forster AJ, et al: Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 57:672-682, 2004
18. Shariff SZ, Cuerden MS, Jain AK, et al: The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 19:841-843, 2008
19. Allison PD: Time dependent covariates, in: Survival Analysis Using SAS: A Practical Guide. Cary, NC, SAS Institute, 2000, pp 138-153
20. Wilmink J, Kordes S, Zwinderman K, et al: A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer. J Clin Oncol 32:5s, 2014 (abstr 4021)